Over the last few days, the US FDA said it was phasing out animal testing.

Instead, the agency will push for the “development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. The new approach is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development (R&D) costs, and ultimately, drug prices,” they said.

That will be replaced by a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a lab setting.

So, it came as no big surprise that AI-driven biotech and health tech firms surged, including:

Recursion Pharmaceuticals (RXRX)

At just $5.50, RXRX is a bargain.

Unlocking the future of biotech with artificial intelligence-powered drug discovery, Recursion Pharmaceuticals is a clinical stage TechBio company decoding biology to industrialize drug discovery – with backing from Nvidia.

What’s most exciting is the company is using generative artificial intelligence to design, synthesize and test novel molecules for efficacy, selectivity, safety and bioavailability.

Enabling the company’s mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. The company leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. 

Sincerely,

Ian Cooper